Sandostatin Shortage: What Providers and Prescribers Need to Know in 2026

Octreotide supply disruptions have created real challenges for clinicians managing patients with acromegaly, carcinoid syndrome, and neuroendocrine tumors. As a prescriber, you need accurate, current information to make timely treatment decisions and help your patients maintain continuity of care. This article provides a comprehensive overview of the shortage status, prescribing implications, therapeutic alternatives, and the tools available to help your patients.

Current Shortage Status (2026)

As of 2026, the octreotide supply landscape is as follows:

• Immediate-release injection: Available from Avet, Fresenius Kabi, Hikma, and Sagent (intermittently). Sagent has reported manufacturing delays. Generally the most accessible formulation.
• Sandostatin LAR Depot (Novartis): Generally available but subject to periodic allocation; regional variability is significant.
• Teva generic octreotide LAR: FDA-approved October 2024. The 20 mg kit experienced backorder through late 2025; production is expected to stabilize in 2026. Bioequivalent to Sandostatin LAR Depot.
• Viatris generic octreotide LAR: FDA-approved in 2025, adding a third manufacturer to the LAR market. Supply ramping up.

Shortage Timeline: How We Got Here

Understanding the multi-year trajectory helps contextualize current supply constraints:

• 2020–2021: Generic immediate-release supply disruptions. Sun Pharma discontinued Bynfezia Pen.
• 2022–2023: Sandostatin LAR Depot intermittent availability issues. Demand pressure from rising NET diagnoses.
• October 2024: Teva's generic LAR approved — first generic competitor to Sandostatin LAR Depot. Teva 20 mg kit subsequently backordered through late 2025.
• 2026: Supply improving with Viatris entering market; inconsistency by region persists.

Clinical Prescribing Strategies During the Shortage

The shortage creates several prescribing decision points for clinicians:

Strategy 1: Bridge With Immediate-Release Octreotide

When the LAR formulation is unavailable, bridging with subcutaneous immediate-release octreotide is a well-established approach. The recommended protocol: 100–200 mcg SC administered 2–3 times daily, depending on the patient's previous LAR dose and their clinical response. Because immediate-release octreotide is available from multiple generic manufacturers, it is significantly more reliably sourced.

Ensure patients understand self-injection technique and have adequate supplies before transitioning. The shift from once-monthly to 2–3 times daily injections requires patient education and may affect adherence.

Strategy 2: Prescribe Generic Octreotide LAR Explicitly

Teva's generic octreotide LAR is bioequivalent to Sandostatin LAR Depot. For patients currently on brand Sandostatin LAR, explicitly prescribing generic octreotide LAR (and allowing generic substitution) can open access to different distribution channels. Note that pharmacy-level substitution policies vary by state and payer. When switching between products, document the shortage as clinical rationale if a new prior authorization is triggered.

Strategy 3: Switch to Lanreotide (Somatuline Depot)

When octreotide is unavailable in any formulation, lanreotide (Somatuline Depot or generic lanreotide) is the primary therapeutic alternative. Lanreotide is manufactured by Ipsen on an independent supply chain, making it a practical backup. Clinical evidence supports comparable efficacy for acromegaly, carcinoid syndrome, and GEP-NETs.

Dosing conversion from octreotide LAR to lanreotide is not a direct milligram-for-milligram switch. A reasonable starting point:

• Octreotide LAR 10 mg → Lanreotide 60 mg q4weeks
• Octreotide LAR 20 mg → Lanreotide 90–120 mg q4weeks
• Octreotide LAR 30 mg → Lanreotide 120 mg q4weeks

Monitor GH/IGF-1 levels (acromegaly) or symptom control (carcinoid/NETs) at 3 months post-switch. Document the shortage as clinical justification to facilitate expedited prior authorization.

Strategy 4: Step Up to Pasireotide LAR for Inadequately Controlled Acromegaly

For acromegaly patients who were already inadequately controlled on first-generation SSAs, the shortage may be an appropriate moment to step up to pasireotide LAR (Signifor LAR). Pasireotide binds SSTR1, 2, 3, and 5 — providing broader receptor coverage and superior biochemical control in treatment-resistant patients. The key limitation is a significantly higher rate of hyperglycemia, requiring additional glucose monitoring.

Prior Authorization and Formulary Considerations

Most commercial and government payers require prior authorization for octreotide and its alternatives. Common payer requirements include:

• Prescription by or in consultation with an endocrinologist, oncologist, or gastroenterologist.
• Step therapy: documentation of trial with generic immediate-release octreotide before LAR or brand formulations.
• Clinical documentation of an FDA-approved or compendia-supported indication.
• Specialty pharmacy dispensing for LAR formulations.

When switching between octreotide products or to an alternative due to shortage, most payers will expedite prior authorization with appropriate documentation of the shortage as the clinical rationale. Pharmacy-level AB-rated generic substitution (octreotide LAR to generic octreotide LAR) typically does not require a new prior authorization.

Lutetium Lu 177 Dotatate Interaction: Critical Prescribing Alert

For patients with GEP-NETs who are receiving or transitioning to lutetium Lu 177 dotatate (Lutathera): octreotide competitively binds somatostatin receptors and can interfere with the efficacy of Lu 177 dotatate. Sandostatin Injection must be discontinued at least 24 hours before each Lutathera dose. Sandostatin LAR Depot should be replaced with short-acting octreotide per protocol before initiating Lu 177 dotatate treatment.

Patient Resources and Financial Assistance

As a prescriber, directing your patients to appropriate financial resources can meaningfully improve access:

• Novartis Patient Support (1-800-277-2254): Copay assistance up to $15,000/year for commercially insured patients. Patient Assistance Foundation for uninsured/underinsured.
• PAN Foundation: Copay assistance for neuroendocrine tumor patients.
• HealthWell Foundation: Grants for acromegaly or neuroendocrine tumor patients covering copays and, in some cases, insurance premiums.
• medfinder for providers: medfinder.com/providers offers provider tools to help your patients locate pharmacies with Sandostatin in stock near them — reducing call burden on your office.

Looking Ahead: Outlook for Octreotide Supply

The growing number of approved LAR manufacturers (Teva and Viatris joining Novartis) is expected to reduce the risk of future supply crises. The adoption of Mycapssa for appropriate acromegaly patients may also reduce pressure on injectable supply. However, the manufacturing complexity of the microsphere formulation means that supply vulnerability will persist. Clinicians should continue to monitor FDA and ASHP shortage databases and maintain therapeutic contingency plans for high-risk patients. Read our full Sandostatin shortage update for patients for additional context to share with your patients.